Marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over [ID6342] Draft guidance Technology appraisal guidance 6 February 2025 Capivasertib with fulvestrant ...

NICE, in collaboration with other international health technology assessment agencies, has published a new report which ...

For further information on the guideline development process, please see how we develop NICE guidelines ...

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

For the first time, NICE has recommended an innovative new treatment to help stop babies, children and young people who are undergoing cancer treatment from losing their hearing. We’ve issued final ...

All NICE products on COVID-19. Includes any guidance and advice.

If you are interested in getting a health technology evaluated by NICE you should ensure that the product is registered with the NHS Innovation Service. That will ensure that it is considered in the ...

A list of downloadable documents created during development.

We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.

We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...